Teza Capital Management LLC Has $6.73 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Teza Capital Management LLC increased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 90,836 shares of the medical research company's stock after buying an additional 10,997 shares during the period. Edwards Lifesciences comprises about 1.0% of Teza Capital Management LLC's investment portfolio, making the stock its 11th largest position. Teza Capital Management LLC's holdings in Edwards Lifesciences were worth $6,725,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock worth $1,007,520,000 after purchasing an additional 126,194 shares during the period. Fisher Asset Management LLC lifted its position in shares of Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock worth $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Edwards Lifesciences in the 4th quarter worth about $610,895,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EW. Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Robert W. Baird boosted their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday, April 24th. Finally, Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of "Hold" and an average price target of $80.20.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the transaction, the vice president now directly owns 33,496 shares in the company, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,692 shares of company stock worth $4,822,074. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

NYSE EW traded down $0.06 on Friday, reaching $74.73. The company's stock had a trading volume of 1,829,009 shares, compared to its average volume of 5,121,504. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm's 50 day moving average is $72.69 and its two-hundred day moving average is $71.99. The stock has a market cap of $43.84 billion, a PE ratio of 10.72, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.66 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.